Clinical Trials Browser

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02964078 2026-02-10

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Genitourinary

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 2 Completed

78 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

Clinical Trials

REGO-SARC

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

METIMMOX

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

SHIVA

Cabozantinib and Pembrolizumab in Metastatic Pancreas

PRO-CARBO

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

PANTHER

MEDOR

IRCI Gynae Sarcomas, High Grade Uterine Sarcoma

METALLICA

DEBBRAH

SWIPE

MERIBEL

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

EBRAIN-MEL

AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer

IMPACT

ATLANTIC

VIRAGE

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

LoMP II

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

PAKT

NT-NAP-102-1

Study of AK112 in the Treatment of Advanced Gynecological Tumors

Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

IL2HD

CRAFT: The NCT-PMO-1602 Phase II Trial

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

REPROGRAM-01

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

MIMOSA

EVACEL

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

PIPAC EstoK 01